Ganoderic acid A

製品コードS4753 バッチS475301

印刷

化学情報

Synonyms

N/A

Storage
(From the date of receipt)

3 years -20°C powder
1 years -80°C in solvent

化学式

C₃₀H₄₄O₇

分子量

516.67

CAS No.

81907-62-2

Solubility (25°C)*

体外

DMSO

100 mg/mL (193.54 mM)

Ethanol (warmed with 50ºC water bath)

100 mg/mL (193.54 mM)

Water

Insoluble

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension

CMC-NA

≥5mg/ml

Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Ganoderic Acid A (GAA) is an active triangle compound in Ganoderma Lucidum. It can inhibit the JAK-STAT3 signal pathway and inhibit cell proliferation, vitality, and ROS. Ganoderic Acid A has analgesic, antioxidant, cytotoxicity, protecting liver and anti -tumor activity.
in vitro	GAA exhibits antitumor activity on human osteosarcoma, lymphoma, meningioma and breast cancer cells through suppressing growth and invasive behavior and/or inducing apoptosis of cancer cells. GAA could also enhance chemosensitivity of HepG2 cells to Cisplatin^[1]. GA-A treatment induces caspase-dependent apoptotic cell death characterized by a dose-dependent increase in active caspases 9 and 3, up-regulation of pro-apoptotic BIM and BAX proteins, and a subsequent loss of mitochondrial membrane potential with release of cytochrome c. Lower doses of GA-A enhance HLA class II-mediated antigen presentation and CD4+ T cell recognition of lymphoma in vitro^[2].
in vivo	GAA can significantly prolong the survival of EL4 syngeneic mice and decrease tumor metastasis to the liver, and enhance cell-mediated immune responses by attenuating myeloid-derived suppressor cells. GAA could undergo extensive metabolism, including reduction, oxidation, and hydroxylation phase I metabolism, and glucuronidation and sulfation phase II metabolism^[1].

プロトコル(参考用のみ)

細胞アッセイ	細胞株	Human pre-B acute lymphocytic leukemia (NALM-6), Burkitt lymphoma (Ramos, GA-10, CA-46 and Daudi) and non-Hodgkin
	濃度	5, 10, 20, and 40μM
	反応時間	24 h
	実験の流れ	Cells are seeded at 1×10⁴ cells/well in 100μl of appropriate culture medium in a flat-bottom 96-well plate. GA-A is added to appropriate wells for final concentrations of 5, 10, 20, and 40μM. Following 24h of GA-A treatment, cell viability is measured using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS).
動物実験	動物モデル	Male Sprague-Dawley rats
	投薬量	20 mg/kg
	投与方法	i.v.

参考

https://pubmed.ncbi.nlm.nih.gov/28326038/
https://pubmed.ncbi.nlm.nih.gov/25142864/

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。